EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Design, development, and therapeutic applications of PARP-1 selective inhibitors

Yue Xu, Xiangqian Li, Yuanyuan Zhao, Chao Xie, Jiashu Chen, Yuxi Lin, Pan Xing, Jiqiang Zhu, Bokan Wang, Dayong Shi

Future Medicinal Chemistry · 18.10.2025 · 17 (20) · 2511-2525

DOI: 10.1080/17568919.2025.2561467 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Future Medicinal Chemistry, online erschienen am 15.09.2025. Verfasst von Yue Xu und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Microbial Technology, Shandong University, Qingdao, Shandong, P. R. China. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerase Inhibitors, Poly (ADP-Ribose) Polymerase-1, Drug Design, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 122 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Shenzhen Fundamental Research Program, National Key Research and Development Program of China, Key R&D Program of Shandong Province, China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Poly(ADP-ribose) polymerase (PARP) plays a key role in DNA damage repair and has become a critical target for tumor therapy. In recent years, several PARP inhibitors, such as Olaparib and Niraparib, have achieved clinical success in breast cancer susceptibility genes (BRCA) mutant tumors by exploiting the synthetic lethality of homologous recombination-deficient cancers. However, problems have emerged in clinical application, such as hematologic toxicity, which may be related to the lack of subtype selectivity of PARP-1/-2. Selective inhibitors of PARP-1 that can overcome toxicity have emerged as a new strategy for PARP inhibitor development. In this review, we first reveal the conformational heterogeneity of the PARP-1/-2 active region through homology comparison and systematically explain the spatial topological characteristics of its selective binding pockets. Then, the structure-activity relationships of 14 reported selective inhibitors of PARP-1 are analyzed to reveal the key pharmacophores occupying the active region, as well as to characterize the specific groups bound to the selective binding domain. Finally, we discuss the structural requirements of selective PARP-1 inhibitors and propose the "secondary site contact" design strategy for the development of new PARP inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Poly(ADP-ribose) Polymerase InhibitorsPoly (ADP-Ribose) Polymerase-1Drug DesignAntineoplastic AgentsDrug DevelopmentHumansStructure-Activity RelationshipNeoplasmsAnimals

Stichwörter der Autor:innen

Tumor therapyhematologic toxicityhomology comparisonselective PARP-1 inhibitorsstructure-activity relationships

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsPoly (ADP-Ribose) Polymerase-1Antineoplastic AgentsPARP1 protein, human

Autor:innen und Institutionen

  • State Key Laboratory of Microbial Technology, Shandong University, Qingdao, Shandong, P. R. China.
  • Shenzhen Research Institute of Shandong University, Shenzhen, Guangdong, P. R. China.
  • Lead High Technology (QingDao) Co., Ltd., Qingdao, Shandong, P. R. China.
  • Shandong Lead High Biotechnology Co., Ltd., Jinan, Shandong, P. R. China.
  • Laboratory for Marine Drugs and Bioproducts, Qingdao Marine Science and Technology Center, Qingdao, Shandong, P. R. China.

Förderung

  • Shenzhen Fundamental Research Program
  • National Key Research and Development Program of China
  • Key R&D Program of Shandong Province, China
  • Natural Science Foundation of Shandong Province

Zitieren

APA

Xu, Y., Li, X., Zhao, Y., Xie, C., Chen, J., Lin, Y., Xing, P., Zhu, J., Wang, B., & Shi, D. (2025). Design, development, and therapeutic applications of PARP-1 selective inhibitors. Future Medicinal Chemistry, 17(20), 2511-2525. https://doi.org/10.1080/17568919.2025.2561467

Vancouver

Xu Y, Li X, Zhao Y, Xie C, Chen J, Lin Y, et al. Design, development, and therapeutic applications of PARP-1 selective inhibitors. Future Medicinal Chemistry. 2025;17(20):2511-2525. doi:10.1080/17568919.2025.2561467

BibTeX
@article{Xu2025,
  author = {Xu, Yue and Li, Xiangqian and Zhao, Yuanyuan and Xie, Chao and Chen, Jiashu and Lin, Yuxi and Xing, Pan and Zhu, Jiqiang and Wang, Bokan and Shi, Dayong},
  title = {Design, development, and therapeutic applications of PARP-1 selective inhibitors},
  journal = {Future Medicinal Chemistry},
  year = {2025},
  volume = {17},
  number = {20},
  pages = {2511--2525},
  doi = {10.1080/17568919.2025.2561467}
}
Kostenlos starten →